Sanofi India Limited (SANOFI) — Financial Results(2 announcements)

Sanofi India reported unaudited Q1 FY26 revenue of ₹4,767 million, up from ₹4,226 million in Q4 FY25 and ₹5,392 million in Q1 FY25. Net profit rose to ₹1,026 million from ₹634 million YoY, driven by strong insulin growth and operational efficiency. The Board approved Mr. Rahul Bhatnagar as new Chairman effective April 30, 2026, and reappointed Independent Directors Aditya Narayan and Usha Thorat until April 29, 2026. The company highlighted stabilizing export sales and continued focus on diabetes therapies despite partnership transitions.

Sanofi India reported revenue of ₹4,767 million for Q1 March 2026, up from ₹4,226 million in Q4 December 2025 and ₹5,392 million in Q1 March 2025. Net profit reached ₹1,026 million, compared to ₹634 million in Q4 2025 and ₹1,195 million in Q1 2025. The company highlighted double-digit growth in its insulin portfolio and strategic partnership transitions impacting results. Board changes included the appointment of Mr. Rahul Bhatnagar as Chairman effective 30 April 2026 and re-constitution of key committees. The press release confirmed the unaudited financial results and limited review by auditors.